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manifestations in relation to the patient’s clinical course and treatment. 
This overview provides the reader with some insight into the various 
mechanisms, their presentation and expected outcomes, with pointers 
that will allow the clinician to make an accurate etiological diagnosis, 
and manage the renal aspects of endocarditis appropriately.
“PRERENAL” FAILURE DUE TO INSUFFICIENT 
RENAL PERFUSION, AND ISCHEMIC ACUTE 
TUBULAR NECROSIS
Renal hypoperfusion due to causes such as septic shock, cardiac failure 
and arrhythmia results in poor effective perfusion of the kidneys and 
leads to a clinical picture of “prerenal” renal failure(3). A biopsy performed 
at this stage would reveal nothing but histological normal glomeruli 
and tubuli(4), despite serum urea and creatinine values refl ecting 
progressively worsening kidney function. The renal medulla is very 
vulnerable to ischemic injury, and suffi ciently prolonged ischemia quickly 
leads to acute tubular necrosis (ATN).(5) Despite its high oxygen 
requirements due to intense metabolic activity, it receives only 20% of 
total renal blood fl ow. The medullary oxygen partial pressure is 
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This review on renal involvement 
associated with infective endocarditis offers clinicians insight 
into the pathophysiology behind each major mechanism of 
the renal disease. It briefl y discusses the treatment of the 
various forms of renal disease, and describes pitfalls in the 
management of endocarditis that may signifi cantly worsen 
the renal outcome. A practical approach is provided, based 
on the timing of onset of the renal disease, the patient’s 
history, and the correct interpretation of various clinical and 
biochemical parameters. 
ABSTRACT
RENAL DISEASE 
ASSOCIATED WITH 
ENDOCARDITIS
INTRODUCTION                                                                  
Kidney dysfunction and subsequent acute renal failure commonly occur, 
and is usually multifactorial in patients with infective endocarditis 
(Table 1). The incidence of renal disease in endocarditis varies: a 
retrospective study in 1998 showed that approximately one-third of 
patients developed acute renal failure(1), while a recent study in the 
Western Cape showed renal involvement to occur in 59.6% of cases.(2) 
Though the true impact of infective endocarditis as a cause of end-
stage kidney disease has not been established, it is well known that the 
outcome may vary from sub-clinical manifestations to a fulminant 
course. Distinguishing between the various causes requires a thorough 
history and examination in order to establish the timing of the renal 
TABLE 1: Mechanisms of renal disease in infective endocarditis
“Prerenal” failure due to insuffi cient renal 
perfusion 
Acute tubular necrosis (ATN)
Acute interstitial nephritis (AIN)
Circulating immune complex mediated
Embolic phenomena / hematogenous 
seeding of infection
Pathophysiological mechanisms Causes
Congestive cardiac failure
Cardiac arrhythmias
Hypotensive shock (due to sepsis or 
cardiac dysfunction)
Intraoperative cardiac arrest
Prolonged intraoperative hypotension and 
ischemia
Altered hemodynamics due to 
prostaglandin inhibition by NSAIDS
Ischemic ATN due to insuffi cient renal               
perfusion or NSAIDS 
Nephrotoxic ATN due to antibiotics such 
as gentamycin, amphotericin B
Drugs: vancomycin, methicillin, rifampicin, 
NSAIDs
Radiocontrast agents
Endocarditis-associated glomerulonephritis
Renal infarcts and abscesses
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extremely low(5) and the balance between oxygen supply and demand 
is very delicate. In addition to ischemic stresses, fl uid restriction, 
exposure to radiocontrast media and potentially nephrotoxic drugs or 
pre-existing chronic kidney disease (CKD) can all act in concert to 
increase the progression to ATN and worsen the outcome.(3, 4) 
Though it may sometimes be diffi cult, it is possible to distinguish 
prerenal renal failure from either ischemic or nephrotoxic ATN by using 
a set of parameters based on pathophysiological changes in these 
conditions (Table 2). It is important to note that none of these 
parameters on its own is suffi cient to differentiate between prerenal 
renal failure and ATN – hence the need to combine as many parameters 
as are available. Both prerenal renal failure and ATN are heralded by 
poor urine output or oliguria and azotemia either at presentation or in 
the course of management.(3, 4) While oliguria is universal in prerenal 
renal failure, ATN may present with oliguria or normal urine volume, 
especially when due to nephrotoxins (e.g. gentamycin). Renal 
reabsorption of urea, sodium and water is increased in prerenal renal 
failure and impaired in ATN, the key difference being preserved tubular 
function in the former. The normal serum urea: creatinine ratio of 1:20 
is preserved in ATN.When underperfused, there is a decrease in tubular 
fl ow rate. The subsequent increased reabsorption of urea (a much 
smaller molecule than creatinine) in intact tubules results in a 
disproportionate increase in urea relative to creatinine. The result is a 
urea: creatinine ratio of 1:10 or more in prerenal failure. Microscopic 
examination of urine in prerenal renal failure is essentially normal, while 
the classic fi nding in ATN is muddy brown granular and tubular epithelial 
cell casts due to sloughing-off of tubular cells into the lumen. In mild non-
oliguric ATN without extensive tubular damage, microscopy may reveal 
only scanty granular or epithelial cast formation or even be normal.(6, 7) 
Careful scrutiny of urine chemistry results may provide useful additional 
information (Table2). Due to the loss of tubular functions of 
concentration and dilution, in ATN the urine osmolality will usually 
approach that of plasma, and sodium will be excreted even in the face 
of hypoperfusion – with the resulting urinary sodium exceeding 
20 meq/L and a fractional excretion of >1%. In contrast, with prerenal 
failure the kidneys compensate by maximally reabsorbing sodium and 
water. This results in a high urine osmolality (usually > 450 mosm/kg) 
and low urine sodium (< 20mosm/L), with the fractional excretion of 
sodium less than 1%. Proteinuria in prerenal renal failure is usually 
normal and always less than 1gram per 24 hours. In ATN proteinuria 
may be up to 2 grams per 24 hours. Neutrophil gelatinase-associated 
lipocalin (NGAL), a newer biochemical parameter that might aid earlier 
detection of ischemic ATN, has recently been described although more 
studies are needed to validate its value.(8, 9) Other possibly useful 
markers are low molecular weight proteins and brush border enzyme, 
which is high in ATN and low in prerenal renal failure. Fractional 
excretion or urea, uric acid and lithium can also be used.(10) 
With the correction of the prerenal factors responsible, recovery of 
renal function in prerenal renal failure will usually occur within 48 to 72 
hours. In ATN, recovery may take weeks and patients may need renal 
replacement therapy as support in the interim. Correction of prerenal 
factors can be as simple as suffi cient intravenous fl uid therapy or 
inotropic support, but may entail surgical correction of valvular 
abnormality or drainage of intracardiac abscesses. Several factors during 
and after surgery, such as anaesthetic agents, prolonged ischemia 
resulting from diffi cult and prolonged surgery, and septic shock, are all 
associated with poorer patient and renal outcomes.(11, 12)
TABLE 2: Diagnostic parameters to differentiate between causes of renal failure 
in endocarditis
Cr; Creatinine concentration in mmol/l, BUN; urea concentration in mmol/l, Na; Sodium concentration, 
FENa: [Urine Na x Plasma Cr / Plasma Na x Urine Cr] x 100, FEurea: [Urine Urea x plasma Cr/ Plasma 
Urea x Urine Cr] x 100.
Adapted from information provided in Lameire N, Van Biesen W, Vanholder R. Acute renal failure. The 
Lancet 2005; 365: 417-430.
 Time of onset At presentation At presentation During At presentation
  or during or during  management  
  management  management
Plasma urea: 1:10 or greater 1:20 1:20 1:20
creatinine ratio
Urine Volume Oliguria Oliguria or  Oliaguria or  Oliguria or  
   Nonoliguria  Nonoliguria  Nonoliguria
Urine Osmolality >450mosm/kg <350mosm/kg - -
Urine Microscopy Normal +/- Muddy granular White cells,  Dysmorphic red
  hyaline casts and epithelial cast eosinophils and  cells and red cell
    white cell casts casts
Urine Na <20meq/L >40meq/L - -
Excretion
Fractional Na <1% >2% - -
Excretion (FENa)
Fractional Urea <35% >35% - -
Excretion(FEurea)
Urine Protein  Normal or  <2g/day <2g/day May be absent 
Estimation <1g/day   OR up to 2g/day
 Parameters Prerenal Renal  Acute Tubular Acute Interstitial Endocarditis-
  Failure Necrosis  Nephritis associated GN
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NEPHROTOXIC ACUTE TUBULAR NECROSIS               
Exposure to potentially nephrotoxic drugs, such as gentamicin, 
vancomycin and rifampicin, can lead to nephrotoxic ATN or 
acute interstitial nephritis (AIN).(13, 14, 15, 16) Nephrotoxic ATN is usually 
dose dependent and occurs through either vasoactive mechanisms 
(e.g. non-steroidal anti-infl ammatory drugs and radiocontrast agent), or 
direct tubular cell damage (e.g. aminoglycosides).
NSAIDS have little effect on kidney function in normal individuals. 
However, in patients already compromised by volume depletion, heart 
failure or pre-existing renal disease, renal perfusion is improved by 
production of vasodilator prostaglandins as an adaptive mechanism. 
NSAIDS prevent the synthesis of these prostaglandins by inhibiting 
cyclooxygenase isoenzymes, thereby decreasing renal blood fl ow. This 
precipitous decline leads initially to prerenal azotemia and, if prolonged 
or severe enough, to ATN.(5)
Radiocontrast material commonly used in cardiac catheterizations and 
computerized tomography (CT) imaging, induce intense vasospasm 
and also have direct tubulotoxic effects. A gradual deterioration in renal 
function may be seen from 24 hours after exposure, though oliguria is 
uncommon. Diabetics with nephropathy, the elderly and patients with 
pre-existing chronic kidney disease are particularly at risk.(17) Astute 
clinicians will minimize injury to their patients by reviewing the estimated 
glomerular fi ltration rate (GFR) of all patients prior to radiocontrast 
studies, identifying those at risk, and by considering alternative imaging 
tests. Standard protective strategies against this form of renal injury 
include intravenous fl uid loading with normal saline 12 hours before 
the contrast study, and the use of N-acetyl cysteine.(17) Apart from 
supportive measures, no specifi c treatment exists once renal injury 
has occurred. 
Aminoglycoside nephrotoxicity is particularly common and tends to 
manifest while the patient is still on the offending agent – often within 
4-5 days from its initiation. Older and female patients are particularly at 
risk, as well as those with pre-existing renal disease, magnesium, 
potassium and calcium defi ciencies, and hypotensive patients with 
intravascular volume depletion.(18) The clinical picture is similar to that 
described with ischemic ATN, but patients are frequently not oliguric. 
Despite its inherent nephrotoxicity, aminoglycosides remain a valuable 
part of the antimicrobial armamentarium. To prevent damage, observant 
clinicians should monitor their patients’ pre-existing renal function and 
adapt drug doses accordingly. Use of a single daily dose of aminoglicoside 
where possible is recommended, as well as reducing the treatment 
course to as short as possible and making intervals between 
aminoglicoside courses as long as possible.(18) The use of any concurrent 
potentially nephrotoxic drugs should be avoided. The diagnosis is usually 
evident from the clinical picture, though when in doubt (and to exclude 
other causes) a renal biopsy may be performed. Myeloid bodies, seen 
by electron microscopy, are pathognomonic. Recovery is slower than 
with typical ATN: serum creatinine takes a median time of 3 weeks to 
return to baseline, and this may be delayed even further if any other 
contributory factors to renal injury are present.
ACUTE INTERSTITIAL NEPHRITIS (AIN)                     
Drug-induced AIN is not dose-dependent but an idiosyncratic reaction, 
and recurrence or exacerbation can occur with a second exposure to 
the same or a related drug. The onset of AIN ranges from three to fi ve 
days with a second exposure to the same offending agent, to as long as 
several weeks with a fi rst exposure.(13, 14, 15) The classical features are 
allergic-type manifestations: fever, a skin rash and eosinophilia occurring 
together or in isolation. In a review of four different series the occurrence 
of the triad was found in less than 10% of cases, while fever, rash and 
eosinophilia occurred more frequently.(19, 20) Other typical fi ndings 
include acute renal insuffi ciency characterized by a sudden rise in serum 
creatinine level that is related to the administration of the offending 
drug. Urine microscopy may show eosinophiluria, white cells, white cell 
casts and red cells. An absence of suggestive sediments does not 
exclude AIN. Daily protein excretion can either be normal or less than 
1g; although nephrotic range proteinuria might be present if due to 
non-steroidal anti-infl ammatory drugs (NSAID) or in the presence of 
other associated conditions that might contribute to the quantity of 
proteinuria.(14) 
Renal biopsy is indicated only if there is no response within one week 
of discontinuation of the offending drug, diagnostic uncertainty or 
advanced renal failure.(20) Histology typically reveals interstitial oedema 
and a marked interstitial infi ltrate consisting primarily of  T-lymphocytes. 
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A monocytic infi ltrate, eosinophils, plasma cells and granulomas have 
also been found. Although not specifi c, a positive Gallium 67 scan be 
used to distinguish AIN from ATN.(21) Recovery of renal function after 
discontinuation of the offending agent might be evident within one 
week in a majority of cases and further evaluation is not necessary in 
responsive cases.(22) Though no randomized controlled trials are 
available to show proven benefi t, corticosteroids can be used in biopsy- 
proven cases or commenced empirically in cases where biopsy is not 
deemed suitable. Clinical and histologic indicators of a decreased 
likelihood of recovery include prolonged renal failure (greater than 
three weeks), AIN associated with NSAID use, and a biopsy showing 
interstitial granulomas, interstitial fi brosis, and tubular atrophy.(23, 24)
ENDOCARDITIS-ASSOCIATED                                  
GLOMERULONEPHRITIS
Patients commonly develop a form of post-infectious glomerulonephritis 
due to circulating immune-complexes. It may occur in both acute and 
sub-acute endocarditis. The exact incidence of this entity is not known 
because of a lack of suffi cient prospective studies(25). The prevalence 
and the type of causal organism associated with glomerulonephritis 
have varied considerably over time, since the introduction of antibiotic 
treatment.(26, 27, 28, 29) Renal deterioration is usually evident at presentation 
and worsens progressively without treatment. It occasionally progresses 
to end-stage renal failure when undetected or left untreated.
Examination by urinary dipstix usually reveals hematuria with or without 
proteinuria. Microscopy of the urine typically demonstrates dysmorphic 
red blood cells. Though not always present, red blood cell casts are 
considered diagnostic. The development of an overt nephrotic 
syndrome is unusual, but may occur in up to 30% of patients with shunt 
nephritis.(30) Several serological laboratory tests may aid the diagnosis. 
Elevated circulating immune complexes are demonstrated in up to 
90% of cases,(31,32,33) and a positive rheumatoid factor in 10-70%. 
Hypocomplementemia is found in about 68-90% of diffuse and 60% of 
focal glomerulonephritis associated with endocarditis,(25, 27) indicating 
activation of the classic complement pathway. Mixed cryoglobulins are 
found in 95% of patients with endocarditis, but correlation with 
glomerulonephritis has not yet been established.(32, 33, 34) Recent 
literature describes cases of anti-cytoplasmic antibody (ANCA) positive 
endocarditis-associated glomerulonephritis, usually presenting with 
rapidly progressive renal failure.(35-39) 
The typical glomerular lesions are focal proliferative and diffuse 
proliferative glomerulonephritis associated with increased cellularity in 
the mesangial and endothelial portion, with or without crescents.(25-27) 
Diffuse crescentic glomerulonephritis has also been reported.(39-41) 
Appropriate antibiotic therapy usually results in recovery of renal 
function. The recovery may be rapid with return to or near baseline in 
mild cases, though hematuria and proteinuria may persist for months. 
The severity of glomerulonephritis is often determined by prolonged 
disease and delayed commencement of antibiotic treatment.(25) 
Progression to end-stage renal failure has been associated with 
crescentic glomerulonephritis and occasionally diffuse proliferative 
glomerulonephritis, while it is uncommon with focal glomerulonephritis, 
which usually presents with mild renal failure.(27, 42) Treatment of severe 
cases may require the use of immunosuppressive therapy such as 
steroids.(40, 41) Treatment of isolated cases with plasmapheresis, in 
addition to antibiotic and steroid therapy, has also been described.(43, 44) 
Little is known about the effect of surgical intervention on the recovery 
of glomerulonephritis,(40) though correction of valvular lesions may 
correct other contributory factors to renal failure.
EMBOLIC PHENOMENA AND ABSCESSES                      
Renal infarction and abscess formation arise from arterial embolization 
of vegetation or hematogenously seeded focal infection. These 
conditions were more common in the pre-antibiotic era, with one 
study revealing an incidence of 56% on autopsy.(45) The frequency of 
embolic events reduced signifi cantly with the advent of antibiotic 
treatment, though it may still be found in Staphylococcus aureus 
endocarditis and in cases where antibiotic therapy was delayed. Embolic 
renal infarcts may be asymptomatic or manifest clinically as fl ank pain 
with hematuria and pyuria but rarely causes renal dysfunction. Associated 
clinical fi ndings include other evidences of embolic phenomena such as 
Osler’s nodes, Roth’s spots and Janeway lesions; as well as abscesses in 
other organs – most commonly the spleen, bowel or brain. No current 
studies on outcomes are available.
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PUTTING THEORY TO GOOD USE: A PRACTICAL 
APPROACH
Appropriate treatment of renal dysfunction can only be offered once 
the aetiology has been established. Three important factors can guide 
the astute clinician to the correct diagnosis: the timing of renal 
manifestations, the patient’s concurrent history and the urinary fi ndings 
(both microscopy and biochemistry). Timing already provides an 
essential means to distinguish between several causes: endocarditis-
associated nephritis is typically present at the time of diagnosis of 
infective endocarditis,(46) and near its peak of severity just before the 
institution of appropriate antibiotic therapy, whereas both acute 
interstitial nephritis and aminoglycoside-induced ATN require at least 
three to fi ve days and, in the former, up to several weeks of admini-
stration of the culprit drug. Renal emboli can occur as late as several 
months after bacteriologic cure.
The patient’s concurrent history can help identify culprit drugs, and 
reveal the presence of sepsis, shock, or cardiac failure giving rise to renal 
hypoperfusion, which may in turn lead to either prerenal failure or 
ischemic ATN. Urinary fi ndings (as described extensively in the 
preceding paragraphs dealing with prerenal failure and ischemic ATN, 
and in Table 2) will further assist in coming to the right conclusions. The 
urinary fi ndings of prerenal failure refl ect intact tubular function and will 
thus show bland urine on microscopy, and highly concentrated urine 
with a very low sodium concentration, while in ATN the microscopy 
shows granular casts and an inability to concentrate or dilute urine. The 
presence of dysmorphic red blood cells and red cell casts is 
pathognomonic of glomerulonephritis. While proteinuria of up to 2 
grams per day may occur in the tubular damage following either ATN 
or interstitial nephritis, nephrotic range proteinuria should prompt one 
towards the diagnosis of a glomerulonephritis.
Prompt correction of the factors responsible for either prerenal failure 
or ATN, along with the initiation of the appropriate antibiotics, remain 
the cornerstone of therapy. The avoidance of any further renal insults 
needs to be stressed, and the astute clinician would do well to avoid 
administering any nephrotoxic drug (or radio contrast) unless no 
alternative exists. A renal biopsy may be indicated where the cause of 
renal failure is not apparent, in cases of progressive renal dysfunction 
despite optimal therapy, or to determine the viability of renal recovery 
after prolonged failure.  
While patients with prerenal failure will recover function rapidly, patients 
with other forms of renal failure may need weeks to recover. At this 
stage it remains imperative to carefully document daily intake and 
output, ensure optimal blood pressure and limit the patient’s salt and 
potassium intake. It is best to involve a nephrologist early in the care 
and decisions of patients who do not show rapid recovery. Supportive 
dialysis therapy may be indicated, though the exact timing of initiation 
of dialysis remains unclear.(47) While most textbooks still state the 
indications as “symptoms or signs of the uremic syndrome, management 
of refractory hypervolemia, -kalemia or acidosis, or a serum urea 
exceeding 35 mmol/L”, a recent study of 52 units in 23 countries 
revealed a much more aggressive dialysis strategy in all participants.(48) 
Oliguria or anuria for as little as 12 hours, in the absence of reversible 
prerenal factors, is now considered by many as a suffi cient indication to 
initiate renal support.(5, 47, 49)  
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